BioLineRx (NASDAQ:BLRX) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Wednesday, Benzinga reports. HC Wainwright currently has a $21.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com raised shares of BioLineRx to a sell rating in a report on Friday, April 12th.

BioLineRx Price Performance

NASDAQ:BLRX opened at $0.66 on Wednesday. BioLineRx has a 52 week low of $0.61 and a 52 week high of $2.53. The firm has a market cap of $52.48 million, a price-to-earnings ratio of -0.73 and a beta of 1.38. The firm’s 50-day simple moving average is $1.06 and its 200 day simple moving average is $1.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.47 and a current ratio of 1.53.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same period in the prior year, the business posted ($0.09) earnings per share. As a group, sell-side analysts predict that BioLineRx will post -1.03 earnings per share for the current year.

Hedge Funds Weigh In On BioLineRx

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in BioLineRx by 278.0% in the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 189,678 shares during the period. LPL Financial LLC increased its holdings in BioLineRx by 6.4% in the 2nd quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 7,500 shares during the period. Atria Wealth Solutions Inc. acquired a new stake in shares of BioLineRx in the 1st quarter valued at approximately $178,000. Envestnet Asset Management Inc. acquired a new stake in shares of BioLineRx in the 1st quarter valued at approximately $88,000. Finally, PVG Asset Management Corp acquired a new stake in shares of BioLineRx in the 4th quarter valued at approximately $97,000. 1.56% of the stock is owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.